Literature DB >> 11919240

Tumor vascularity in the prognostic assessment of primary cutaneous melanoma.

Mohammed Kashani-Sabet1, Richard W Sagebiel, Carlos M M Ferreira, Mehdi Nosrati, James R Miller.   

Abstract

PURPOSE: The vascular supply of the primary tumor is recognized to play an important role in the progression of a number of solid tumors. However, the role of tumor vascularity in the prognostic assessment of melanoma remains unclear. The purpose of this study was to determine the prognostic impact of patterns of vascularity on the outcome associated with cutaneous melanoma. PATIENTS AND METHODS: Tumor vascularity was documented prospectively using routine histopathologic analysis of 417 primary cutaneous melanomas from the University of California at San Francisco Melanoma Center database. Four patterns of tumor vascularity were recorded: absent, sparse, moderate, and prominent.
RESULTS: Increasing tumor vascularity significantly increased the risk of relapse and death associated with melanoma, corresponding to reduced relapse-free and overall survival. By multivariate analysis, tumor vascularity was the most important determinant of overall survival, surpassing tumor thickness. Increasing tumor vascularity was associated with increased incidence of ulceration in the primary tumor.
CONCLUSION: Tumor vascularity is an important prognostic factor in melanoma, rivaling tumor thickness. Increasing tumor vascularity is highly correlated with ulceration, possibly helping to explain the biologic basis of this known prognostic factor.

Entities:  

Mesh:

Year:  2002        PMID: 11919240     DOI: 10.1200/JCO.2002.07.082

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Interval sentinel lymph nodes in melanoma: a digital pathology analysis of Ki67 expression and microvascular density.

Authors:  Christian Marinaccio; Giuseppe Giudice; Eleonora Nacchiero; Fabio Robusto; Giuseppina Opinto; Gaetano Lastilla; Eugenio Maiorano; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2015-08-15       Impact factor: 3.984

2.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

3.  S100A13 is a new angiogenic marker in human melanoma.

Authors:  Daniela Massi; Matteo Landriscina; Annamaria Piscazzi; Elena Cosci; Alek Kirov; Milena Paglierani; Claudia Di Serio; Vasileios Mourmouras; Stefano Fumagalli; Maurizio Biagioli; Igor Prudovsky; Clelia Miracco; Marco Santucci; Niccolò Marchionni; Francesca Tarantini
Journal:  Mod Pathol       Date:  2010-03-05       Impact factor: 7.842

4.  Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Authors:  Kriti Mittal; Henry Koon; Paul Elson; Pierre Triozzi; Afshin Dowlati; Helen Chen; Ernest C Borden; Brian I Rini
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

5.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

Review 6.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

7.  Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.

Authors:  Uma N M Rao; Sandra J Lee; Weixiu Luo; Martin C Mihm; John M Kirkwood
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

8.  A multimarker prognostic assay for primary cutaneous melanoma.

Authors:  Mohammed Kashani-Sabet; Suraj Venna; Mehdi Nosrati; Javier Rangel; Antje Sucker; Friederike Egberts; Frederick L Baehner; Jeff Simko; Stanley P L Leong; Chris Haqq; Axel Hauschild; Dirk Schadendorf; James R Miller; Richard W Sagebiel
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

9.  sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.

Authors:  Mitchell E Fane; Brett L Ecker; Amanpreet Kaur; Gloria E Marino; Gretchen M Alicea; Stephen M Douglass; Yash Chhabra; Marie R Webster; Andrea Marshall; Richard Colling; Olivia Espinosa; Nicholas Coupe; Neera Maroo; Leticia Campo; Mark R Middleton; Pippa Corrie; Xiaowei Xu; Giorgos C Karakousis; Ashani T Weeraratna
Journal:  Clin Cancer Res       Date:  2020-11-01       Impact factor: 12.531

10.  Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis.

Authors:  Xiaowei Xu; Phyllis A Gimotty; Dupont Guerry; Giorgos Karakousis; Patricia Van Belle; Haohai Liang; Katharine Montone; Terry Pasha; Michael E Ming; Geza Acs; Michael Feldman; Stephen Barth; Rachel Hammond; Rosalie Elenitsas; Paul J Zhang; David E Elder
Journal:  Hum Pathol       Date:  2008-04-28       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.